Skip to main content
 

Type 2 diabetes and obesity are linked to an increased risk of certain cancers.  Recently published studies suggested that insulin glargine (a synthetic insulin preparation marketed under the trade name Lantus), may be associated with a higher risk of certain cancers than other insulins or oral glucose lowering medications.  However, these studies were unable to control for important factors such as obesity that may have driven the association. 

Type 2 diabetes and obesity are linked to an increased risk of certain cancers.  Recently published studies suggested that insulin glargine (a synthetic insulin preparation marketed under the trade name Lantus), may be associated with a higher risk of certain cancers than other insulins or oral glucose lowering medications.  However, these studies were unable to control for important factors such as obesity that may have driven the association. 

On the other hand, a large randomized trial designed to examine another aspect of diabetes care, which used insulin glargine in one arm, showed no increase in the frequency of cancer with glargine. For full release

Comments are closed.